Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.29
+0.59351.71%
Post-market: 35.380.0865+0.25%16:00 EDT
Volume:148
Turnover:5K
Market Cap:16.59M
PE:- -
High:35.29
Open:35.23
Low:35.23
Close:34.70
52wk High:37.90
52wk Low:30.79
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.41
T/O Rate:0.03%
Dividend:0.41
Dividend Rate:1.16%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Pre-Holiday Gains: Can This Strong Sector Keep Rising After the Break?

Deep News
·
Sep 30

China Pharma Sector Divergence Deepens as Innovative Drug Leaders Ride BD Second Growth Curve

Deep News
·
Sep 30

Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today?

TIPRANKS
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30

Satellos announces enrollment completed for BASECAMP

TIPRANKS
·
Sep 30

Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia

Reuters
·
Sep 30

Pre-Holiday Rally: Can This Strong Sector Continue to Rise After the Break?

Deep News
·
Sep 30

Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial

TIPRANKS
·
Sep 30

Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Sep 30

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

GlobeNewswire
·
Sep 30

AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart

TIPRANKS
·
Sep 30

AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295

Reuters
·
Sep 30

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS
·
Sep 30

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS
·
Sep 30